Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Journey Medical profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Journey Medical's profit margin for the twelve months ending Sep 30, 2026 was -7.3%. For fiscal 2025 it was -18.5%, against -26.1% the year before. The highest annual figure on record is 11.9% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18.5% | +7.7 |
| FY2024 | Dec 31, 2024 | -26.1% | −21.3 |
| FY2023 | Dec 31, 2023 | -4.9% | +35.4 |
| FY2022 | Dec 31, 2022 | -40.2% | +29.5 |
| FY2021 | Dec 31, 2021 | -69.7% | −81.5 |
| FY2020 | Dec 31, 2020 | 11.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -6.9% | +6.2 |
| Q2 FY2026 | Jun 30, 2026 | -1.7% | +23.6 |
| Q1 FY2026 | Mar 31, 2026 | -14.0% | +17.0 |
| Q4 FY2025 | Dec 31, 2025 | -7.8% | −18.9 |
| Q3 FY2025 | Sep 30, 2025 | -13.1% | +3.2 |
| Q2 FY2025 | Jun 30, 2025 | -25.3% | −2.7 |
| Q1 FY2025 | Mar 31, 2025 | -31.0% | +49.1 |
| Q4 FY2024 | Dec 31, 2024 | 11.2% | +25.2 |
| Q3 FY2024 | Sep 30, 2024 | -16.3% | −64.9 |
| Q2 FY2024 | Jun 30, 2024 | -22.6% | +44.0 |
| Q1 FY2024 | Mar 31, 2024 | -80.1% | −17.6 |
| Q4 FY2023 | Dec 31, 2023 | -14.0% | +27.1 |
| Q3 FY2023 | Sep 30, 2023 | 48.6% | +54.5 |
| Q4 FY2022 | Dec 31, 2022 | -66.7% | +57.5 |
| Q3 FY2022 | Sep 30, 2022 | -62.5% | −8.3 |
| Q2 FY2022 | Jun 30, 2022 | -41.2% | +36.5 |
| Q1 FY2022 | Mar 31, 2022 | -5.9% | −8.4 |
| Q4 FY2021 | Dec 31, 2021 | -124.2% | −142.4 |
| Q3 FY2021 | Sep 30, 2021 | -54.3% | −54.6 |
| Q2 FY2021 | Jun 30, 2021 | -77.6% | – |
| Q1 FY2021 | Mar 31, 2021 | 2.5% | – |
| Q4 FY2020 | Dec 31, 2020 | 18.2% | – |
| Q3 FY2020 | Sep 30, 2020 | 0.3% | – |
See a number that looks wrong?